Global Leading Market Research Publisher QYResearch announces the release of its latest report “Normothermic Perfusion of Isolated Organs – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Normothermic Perfusion of Isolated Organs market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Normothermic Perfusion of Isolated Organs was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032.
Addressing Core Organ Preservation, Extended Cold Ischemia, and Transplant Outcome Pain Points
Organ transplant specialists, organ banks, and pharmaceutical research organizations face persistent challenges: static cold storage (SCS, 4°C) limits organ preservation time (heart 4-6 hours, liver 8-12 hours, kidney 24-36 hours, lung 6-8 hours), leading to organ discard (20-30% of donor organs not transplanted) and poor post-transplant outcomes (delayed graft function, primary non-function). Normothermic perfusion of isolated organs—ex vivo machine perfusion with warm oxygenated blood (35-37°C), nutrients, and hormones—has emerged as the solution for extended preservation time, organ viability assessment, and improved transplant outcomes. However, product selection is complicated by four distinct organ types: heart perfusion, liver perfusion, kidney perfusion, and lung perfusion. Over the past six months, new FDA approvals for normothermic perfusion devices (TransMedics OCS, OrganOx metra), increased utilization of marginal donors (extended criteria donors (ECD), donation after circulatory death (DCD)), and organ preservation research funding have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5737384/normothermic-perfusion-of-isolated-organs
Key Industry Keywords (Embedded Throughout)
- Normothermic organ perfusion
- Heart liver kidney lung
- Organ transplant viability
- Ex vivo machine preservation
- Organ bank logistics
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global normothermic perfusion of isolated organs market is concentrated among a few specialized medical device companies and academic medical centers. Key players include TransMedics (US, Organ Care System (OCS) for heart, lung, liver), Lung Bioengineering (US, ex vivo lung perfusion (EVLP)), OrganOx (UK, metra liver perfusion system), XVIVO (Sweden, heart/lung/kidney perfusion), TNO (Netherlands), UHN (Canada, Toronto EVLP), SCREEN (US), Bridge to Life (US), Organ Recovery Systems (US), Institut Georges Lopez (France), Ebers (Germany), Penn Medicine (US), and Johns Hopkins Medicine (US).
Three recent developments are reshaping demand patterns:
- FDA approvals for normothermic perfusion devices (2024-2025) : FDA approved TransMedics OCS Heart (2024), OCS Lung (2024), OCS Liver (2025). OrganOx metra liver perfusion (FDA cleared 2025). Regulatory approvals expanded clinical adoption.
- Marginal donor utilization (ECD, DCD) : Extended criteria donors (older, comorbidities) and donation after circulatory death (DCD) organs have higher discard rates. Normothermic perfusion assesses viability and improves outcomes, increasing organ utilization by 15-20%.
- Organ preservation research funding (NIH, EU Horizon) : US NIH (National Institutes of Health) and EU Horizon Europe funding for ex vivo organ perfusion research (normothermic, subnormothermic, hypothermic). Research segment grew 10-12% in 2025.
Technical Deep-Dive: Organ Types
- Heart Perfusion (normothermic beating heart preservation). Advantages: extends preservation time (4-6 hours cold static → 8-12 hours normothermic), enables viability assessment (contractility, coronary flow, metabolic parameters), and improves post-transplant outcomes (reduced primary graft dysfunction (PGD)). A 2025 study from the Journal of Heart and Lung Transplantation found that normothermic perfusion reduces PGD by 40-50% vs. cold static storage. Key device: TransMedics OCS Heart. Accounts for approximately 25-30% of normothermic perfusion market value.
- Liver Perfusion (normothermic preservation with oxygenated blood, nutrients, bile production). Advantages: extends preservation time (8-12 hours cold static → 24-48 hours normothermic), assesses viability (bile production, lactate clearance, transaminase levels), and enables DCD liver utilization (increased transplant volume). Key devices: TransMedics OCS Liver, OrganOx metra. Accounts for 30-35% of market value (largest segment).
- Kidney Perfusion (normothermic preservation with urine production assessment). Advantages: extends preservation time (24-36 hours cold static → 48-72 hours normothermic), reduces delayed graft function (DGF), and assesses viability (urine output, creatinine clearance). Accounts for 20-25% of market value.
- Lung Perfusion (ex vivo lung perfusion (EVLP), normothermic ventilation and perfusion). Advantages: extends preservation time (6-8 hours cold static → 12-18 hours normothermic), assesses viability (gas exchange, pulmonary artery pressure), and enables DCD and marginal lung utilization. Key devices: TransMedics OCS Lung, XVIVO, Toronto EVLP (UHN). Accounts for 20-25% of market value.
User case example: In November 2025, a transplant center (high-volume liver transplant program, 200 transplants/year) published results from using normothermic liver perfusion (OrganOx metra, TransMedics OCS Liver) for DCD and marginal livers. The 12-month study (completed Q1 2026) showed:
- Organ type: liver (DCD, extended criteria donors (ECD)).
- Preservation: normothermic perfusion (6-12 hours) vs. cold static storage (4-6 hours).
- Organ utilization: 85% (normothermic) vs. 60% (cold static) (25% increase).
- Post-transplant outcomes: early allograft dysfunction (EAD) 15% (normothermic) vs. 30% (cold static) (50% reduction).
- Cost per perfusion: $5,000-10,000 (device + disposables) vs. cold static $500.
- Payback period (increased organ utilization + improved outcomes): 6-12 months.
- Decision: Normothermic perfusion for DCD/marginal organs; cold static for standard criteria donors (SCD).
Industry Segmentation: Discrete vs. Continuous Manufacturing
- Normothermic perfusion devices (perfusion pumps, oxygenators, heat exchangers, sensors, disposable perfusion sets) follow batch discrete manufacturing (low volume, high value). Production volumes: thousands of units annually.
- Perfusion disposables (single-use tubing sets, oxygenators, reservoirs) are high-volume.
Exclusive observation: Based on analysis of early 2026 product launches, a new “portable normothermic perfusion device” (wearable, battery-operated) for inter-hospital organ transport is emerging for extended transport logistics. Traditional normothermic perfusion devices are large (console, 50-100kg). Portable devices (TransMedics OCS (already portable), OrganOx (tabletop)) enable normothermic perfusion during transport (ambulance, helicopter, small aircraft). Portable devices command 20-30% price premium ($50,000-100,000 vs. $30,000-50,000 for stationary) and target organ procurement organizations (OPOs) with long transport distances.
Application Segmentation: Organ Transplant Specialist Hospitals, Organ Banks, Pharmaceutical Research Organizations
- Organ Transplant Specialist Hospitals (tertiary transplant centers, high-volume programs) accounts for 70-75% of normothermic perfusion of isolated organs market value (largest segment). Heart, liver, kidney, lung perfusion. Growing at 8-10% CAGR.
- Organ Banks (organ procurement organizations (OPOs), regional organ distribution) accounts for 15-20% of value. Heart, lung, liver perfusion (transport logistics). Growing at 10-12% CAGR.
- Pharmaceutical Research Organizations (drug development, toxicity testing, ex vivo organ models) accounts for 5-10% of value. Research perfusion (isolated perfused organ models). Growing at 8-10% CAGR.
Strategic Outlook & Recommendations
The global normothermic perfusion of isolated organs market is projected to reach US$ million by 2032, growing at a CAGR of %.
- Organ transplant specialists (heart, liver, kidney, lung) : Normothermic perfusion for DCD (donation after circulatory death) and marginal organs (extended criteria donors (ECD)) – improves organ utilization (15-25% increase) and post-transplant outcomes (reduced PGD, EAD, DGF). Portable devices for inter-hospital transport (long distances).
- Organ banks (OPOs) : Normothermic perfusion during transport (preservation time extension, viability assessment). OCS Heart/Lung/Liver, OrganOx metra, XVIVO.
- Research organizations (pharmaceutical) : Normothermic perfusion for ex vivo drug testing (liver metabolism, cardiotoxicity, nephrotoxicity, pulmonary toxicity). Isolated organ models reduce animal testing.
- Manufacturers (TransMedics, OrganOx, XVIVO, Lung Bioengineering, Bridge to Life, Organ Recovery Systems, Institut Georges Lopez, Ebers): Invest in portable normothermic perfusion devices (transport logistics), lower-cost disposables ($2,000-5,000 vs. $5,000-10,000), and multi-organ perfusion systems (heart + lung, liver + kidney). FDA approvals (OCS Heart/Lung/Liver, OrganOx metra) expand market.
For organ preservation and transplant outcomes, normothermic perfusion of isolated organs (heart, liver, kidney, lung) extends preservation time, assesses viability, and improves post-transplant outcomes compared to static cold storage. Liver perfusion largest segment; heart, lung, kidney growing. FDA approvals (TransMedics OCS, OrganOx metra) and marginal donor utilization drive adoption.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
